Erasca Receives FDA Clearance for First-in-Class Pan-KRAS Inhibitor, ERAS-4001, for Solid Tumors
Erasca Inc. (NASDAQ:ERAS) is one of the stocks under $10 to buy now. Earlier on June 2, Erasca announced that the US FDA had cleared its Investigational New Drug/IND application for ERAS-4001.